TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $4.34 billion. The enterprise value is $4.52 billion.
Important Dates
The next confirmed earnings date is Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 146.20 million shares outstanding. The number of shares has increased by 11.64% in one year.
| Current Share Class | 146.20M |
| Shares Outstanding | 146.20M |
| Shares Change (YoY) | +11.64% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | 4.56% |
| Owned by Institutions (%) | 74.15% |
| Float | 139.47M |
Valuation Ratios
The trailing PE ratio is 10.80 and the forward PE ratio is 21.27. TG Therapeutics's PEG ratio is 0.14.
| PE Ratio | 10.80 |
| Forward PE | 21.27 |
| PS Ratio | 8.27 |
| Forward PS | 5.15 |
| PB Ratio | 7.17 |
| P/TBV Ratio | 7.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.14 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 10.11 |
| EV / Sales | 8.50 |
| EV / EBITDA | 43.99 |
| EV / EBIT | 44.01 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.42.
| Current Ratio | 3.82 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.43 |
| Debt / FCF | n/a |
| Interest Coverage | 3.77 |
Financial Efficiency
Return on equity (ROE) is 111.96% and return on invested capital (ROIC) is 20.37%.
| Return on Equity (ROE) | 111.96% |
| Return on Assets (ROA) | 7.97% |
| Return on Invested Capital (ROIC) | 20.37% |
| Return on Capital Employed (ROCE) | 11.84% |
| Weighted Average Cost of Capital (WACC) | 14.21% |
| Revenue Per Employee | $1.42M |
| Profits Per Employee | $1.20M |
| Employee Count | 374 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | -359.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.86% in the last 52 weeks. The beta is 1.87, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | +3.86% |
| 50-Day Moving Average | 29.96 |
| 200-Day Moving Average | 32.79 |
| Relative Strength Index (RSI) | 53.58 |
| Average Volume (20 Days) | 1,419,555 |
Short Selling Information
The latest short interest is 28.95 million, so 19.80% of the outstanding shares have been sold short.
| Short Interest | 28.95M |
| Short Previous Month | 27.29M |
| Short % of Shares Out | 19.80% |
| Short % of Float | 20.76% |
| Short Ratio (days to cover) | 12.03 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $531.90 million and earned $447.47 million in profits. Earnings per share was $2.78.
| Revenue | 531.90M |
| Gross Profit | 453.93M |
| Operating Income | 102.78M |
| Pretax Income | 87.75M |
| Net Income | 447.47M |
| EBITDA | 102.83M |
| EBIT | 102.78M |
| Earnings Per Share (EPS) | $2.78 |
Full Income StatementBalance Sheet
The company has $131.58 million in cash and $254.54 million in debt, with a net cash position of -$122.96 million or -$0.84 per share.
| Cash & Cash Equivalents | 131.58M |
| Total Debt | 254.54M |
| Net Cash | -122.96M |
| Net Cash Per Share | -$0.84 |
| Equity (Book Value) | 607.22M |
| Book Value Per Share | 4.26 |
| Working Capital | 442.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.07 million and capital expenditures -$168,000, giving a free cash flow of -$70.24 million.
| Operating Cash Flow | -70.07M |
| Capital Expenditures | -168,000 |
| Free Cash Flow | -70.24M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
Gross margin is 85.34%, with operating and profit margins of 19.32% and 84.13%.
| Gross Margin | 85.34% |
| Operating Margin | 19.32% |
| Pretax Margin | 16.50% |
| Profit Margin | 84.13% |
| EBITDA Margin | 19.33% |
| EBIT Margin | 19.32% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.64% |
| Shareholder Yield | -11.64% |
| Earnings Yield | 10.17% |
| FCF Yield | -1.60% |
Analyst Forecast
The average price target for TG Therapeutics is $50.67, which is 70.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.67 |
| Price Target Difference | 70.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 35.16% |
| EPS Growth Forecast (5Y) | 73.99% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
TG Therapeutics has an Altman Z-Score of 6.79 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.79 |
| Piotroski F-Score | 3 |
